Description

Retatrutide is a first-in-class triple hormone receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. By integrating glucagon receptor agonism with the dual-incretin pathway, Retatrutide represents a significant evolutionary leap beyond Semaglutide and Tirzepatide. It is primarily researched for its unprecedented efficacy in adipose tissue reduction and the modulation of energy expenditure.

Our Retatrutide is 99%+ pure, lyophilized for maximum stability, and vacuum-sealed to ensure consistent research results in advanced metabolic studies.

Key Research Applications & Benefits

• Triple-Pathway Synergy: Simultaneously activates GLP-1, GIP, and Glucagon receptors, providing a unique “tri-modal” approach to metabolic signaling.

• Elevated Energy Expenditure: Unlike single or dual agonists, the inclusion of the glucagon receptor (GCG) allows for the study of increased thermogenesis and metabolic rate.

• Profound Adiposity Modulation: Extensively researched for its ability to achieve significant body mass reduction in shorter research windows compared to previous analogues.

• Liver Health Research: Emerging studies focus on Retatrutide’s potential to reduce hepatic fat content and improve markers of non-alcoholic fatty liver disease (NAFLD).

• Glycemic Stability: Enhances insulin secretion and suppresses glucagon in a glucose-dependent manner, providing a high-fidelity model for Type 2 diabetes research.

Technical Specifications